The United States is witnessing strong adoption of intravenous immunoglobulin (IVIG) therapy due to the rising prevalence of autoimmune diseases, primary immunodeficiency disorders, and neurological conditions. Advanced healthcare infrastructure, widespread availability of plasma-derived therapies, and favorable reimbursement policies continue to support treatment accessibility across...